Regulator: CONIS / ANRS (Comité Nacional de Investigación en Salud (CONIS) of the Ministry of Health (MINSA), with the Autoridad Nacional de Regulación Sanitaria (ANRS) created by Law 1068 (2021))
In Nicaragua, CONIS, the National Committee for Health Research of the Ministry of Health, authorizes clinical trials of medicines under Technical Standard NTON 19001:2022 (La Gaceta No. 225, 30 November 2022) and MINSA Normativa-166 (August 2020), after approval by an ethics committee, the scientific research committee, and the national regulatory authority. Phase I is provided for, with healthy volunteers first and compassionate use only by exception. Section 13.1 lets a foreign product apply only with authorization for research in humans from a recognized international regulator, so Nicaragua fits as a second country after an FDA IND or a first study elsewhere, not as the place to run a first-in-human study first. There are no published device-specific trial rules, although ANRS lists a fee code for authorizing a clinical investigation of a medical device (DDM-10). This guide cites no bioaccess® study, site, entity, or office in Nicaragua. U.S. sanctions on Nicaragua are list-based, so counterparties must be screened, and the U.S. State Department rates Nicaragua Level 3: Reconsider Travel. Sources: NTON 19001 (legislacion.asamblea.gob.ni), Normativa-166 and ANRS documents (minsa.gob.ni), OFAC, and travel.state.gov (official).
NTON 24001:2023 sets sanitary-registration requirements for medical devices to be distributed and sold. It is not a study permit and does not authorize a device investigation. The registration holder is the product owner, who authorizes its local distributor.
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when that rule's conditions are met, including ethics-committee oversight and informed consent. Eligibility is not clearance or approval.
CONIS, the National Committee for Health Research of the Ministry of Health, under NTON 19001:2022 and Normativa-166, after approvals from an ethics committee, the scientific research committee, and the national regulatory authority (ANRS, created by Law 1068).
Not as the first country for a foreign product. NTON 19001:2022 section 13.1 requires authorization for research in humans from a recognized international regulator, so Nicaragua fits as a second country after an FDA IND or a first study elsewhere. Phase I is provided for, with healthy volunteers first, compassionate use by exception, prior animal toxicity including carcinogenicity and teratogenicity, and a facility equipped for Phase I (section 5.2.1).
There are no published device-specific trial rules. ANRS lists a fee for authorizing the clinical investigation of medical devices (code DDM-10, C$10,887.72, Circular ANRS-MLRG-0017-10-2024), and Resolution 0009/2024 requires the CONIS authorization to import products for clinical research. The route is confirmed case by case with ANRS and CONIS.
No total timeline is published. The national regulatory authority has up to 45 business days for its binding technical report when CONIS requests it (Normativa-166, Chapter XI). That is not an ethics clock or a startup promise.
OFAC's Nicaragua-related program is list-based, not a country-wide embargo: it blocks designated persons and entities they own 50 percent or more (31 CFR 582.201 and 582.406). Only listed parties are blocked, so counterparties, sites, banks, and payments must be screened before committing.
This guide does not say that. It cites no bioaccess® entity, office, site, or completed study in Nicaragua. Ask for a protocol-specific feasibility assessment.
All Latin America regulatory guides · Book a free 30-min strategy call